Literature DB >> 34089614

Cohort Profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database.

Rachel H Mulholland1, Eleftheria Vasileiou1, Colin R Simpson1,2, Chris Robertson3,4, Lewis D Ritchie5, Utkarsh Agrawal6, Mark Woolhouse1, Josephine Lk Murray4, Helen R Stagg1, Annemarie B Docherty1, Colin McCowan6, Rachael Wood1,4, Sarah J Stock1, Aziz Sheikh1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34089614      PMCID: PMC8195245          DOI: 10.1093/ije/dyab028

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


× No keyword cloud information.

Why was the cohort set up?

In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020. The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world. There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions. The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and insights into the effectiveness of and safety of vaccines and treatments for COVID-19. This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness)., EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.

Who is in the cohort?

We obtained ethical approval from the National Research Ethics Service Committee, Southeast Scotland 02. This prospective baseline cohort study contains all 5.4 million individuals registered with a general practitioner (GP) in Scotland from 23 February 2020 which, according to the National Records of Scotland (NRS) 2019 mid-year estimates, covers around 98–99% of the Scottish population., A map of the baseline EAVE II cohort by the National Health Service (NHS) Health Board shows that most of the cohort are based in the central belt of Scotland (Figure 1).
Figure 1

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code). A summary of the baseline population by sex, age group (as of 23 February) and deprivation used the Scottish Index of Multiple Deprivation (SIMD) and Scottish Government Urban Rural Classification. SIMD is a measure of deprivation built on seven domains and is unique to Scotland, with lower quintiles representing the most deprived areas. These primary care records are linked to other data sources from out-of-hours, emergency and secondary care. There are additional linkages to other datasets such as laboratory testing data, registration and mortality data, self-reported data and enhanced surveillance data such as the COVID-19 Clinical Information Network (CO-CIN). This is done using the Community Health Index (CHI), the unique identifier provided by NHS Scotland. It is allocated to all residents in Scotland registered with a GP and to all patients who receive care in Scotland, even if they are non-Scottish residents. Summaries of these data sources are given in Table 2, with a data flow diagram on how they are linked together in Figure 2.
Table 2

Details of data sources within the different settings for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort

SettingData sourcesDescription
Primary careGeneral practice (GP) dataaData from all patients registered with GP. GP data (demographic, consultation data—categorized into risk groups, prescribing and categorized measurements) will be extracted using the Enhanced Services Contract Reporting Options (ESCRO) system by the trusted third party Albasoft Ltd10
Prescribing Information System (PIS)aInformation on all prescribing relating to all prescriptions dispensed in the community. Prescriptions written in hospitals which are dispensed in the community are also included20
Out-of-hours (OOH)bData on the services a patient receives for primary care when their registered GP practice is closed21
Scottish Morbidity Record 00 (SMR00)aRelates to all outpatients (new and follow-up) in specialties other than Accident & Emergency (A&E), and Genito-urinary Medicine22
Telephone consultationNational Health Service (NHS) 24aDelivers telephone and online services across Scotland for initial assessments, which are then passed on to the appropriate services if required10
COVID-19 Community Hubs and Assessment Centresb

A network established by NHS Health Boards in Scotland to provide a direct and rapid route of people with COVID-1910. Data from these centres will derive from National Health Service (NHS) 24 and the COVID-19 Enhanced Surveillance dataset10.

Secondary care

Scottish Morbidity Record (SMR) including:

SMR01a

SMR02a

SMR01: Episode-based patient record for all inpatients and day cases discharged from non-obstetric and non-psychiatric specialties in Scotland. This includes Accident & Emergency (A&E) attendances10
SMR02: Episode-based patient record for all inpatients and day cases discharged from obstetric specialties in Scotland10
Scottish Hospital Electronic Prescribing and Medicines Administration (HEMPA) systemaData on prescription and administration of medicines for inpatients from a subgroup of hospitals with HEPMA systems10
Scottish Ambulance Service (SAS) aScottish database for all patients requiring emergency ambulance services or needing support to reach their health care appointments due to their medical and mobility needs23
Scottish Intensive Care Society Audit Group (SICSAG) aScottish database for adult patients admitted to all general intensive care units (ICU) and combined ICU/high dependency units (HDU)10

COVID19 Clinical Information Network/International Severe Acute Respiratory and emerging Infection Consortium

(CO-CIN/ISARIC) p

Data of the clinical characteristics of patients admitted to hospital with COVID-19 infection in Scotland recruited to CO-CIN/ISARIC.24 As of 22 June 2020 this comprised 65% of the hospitalized patients in Scotland
Rapid Preliminary Inpatient Data (RAPID)bContains hospital inpatient admission data which have been used to predict emergency admissions and bed occupancy25
Mortality dataNational Records of Scotland (NRS) deathsaData on Scottish death certificates and the cause of death26
Laboratory and serology dataElectronic Communication of Surveillance in Scotland (ECOSS)aSurveillance data on laboratory results from microorganisms, infections and microbial intoxications. Contains all reverse transcriptase polymerase chain reaction (RT-PCR) tests carried out in Scotland10
Serology dataaAll serology data will be provided by the ‘Seroprevalence’ work carried out and commissioned by the COVID-19 Enhanced Surveillance cell of Public Health Scotland (PHS)10
Genome sequencing databPositive laboratory RT-PCR swab samples for COVID-19 will also be sent to national sequencing centres where 500 COVID-19 genome sequences will be performed10
Self-reported dataTest and Protect databA service which identifies positive cases of COVID-19 and who they have had close, recent contact with27
SurveysbSurveys on how people have been affected by COVID-19 in Scotland
Census 2011 databResidents in Scotland are asked to fill in a census questionnaire every 10 years and provide information on their demographic (e.g. ethnicity), socioeconomic, health and other circumstances. NRS will provide data from the latest Scottish Census in 201128
Derived dataCOVID-19 shielding patient listbUses a combination of primary and secondary care held in Public Health Scotland to derive groups considered to be at high risk if they contract COVID-1929
Births and pregnancy- related dataScottish Birth Record (SBR)bThe SBR is a web-based system developed on the NHSNet to ensure that every baby born in Scotland will have one record which will act as the foundation for future information collection. The system has been implemented to varying degrees in all Scottish hospitals providing midwifery and/or neonatal care30
NHS live birth notificationsbNotification of live births from NHS Board maternity units to child health administration departments31
NRS birthsbRecord of statutory registration of a live birth (live-born baby at any gestation)32
NRS statutory stillbirth registrationsbRecord of statutory registration of a stillbirth (baby born at ≥24 weeks, showing no signs of life)33
NHS antenatal care notificationsbPublic Health Scotland (PHS) has developed a new national data return as part of the response to the COVID-19 pandemic, providing information on women booking for antenatal care with NHS maternity services: for identification of women with ongoing pregnancies in near real-time
Abortion Act Scotland (AAS) NotificationsbRecord of statutory notification of all terminations of pregnancy in Scotland34
Vaccine treatmentChild Health Systems Programme—School (CHSP-S)aFacilitates the call/recall of both primary and secondary school pupils for screening, review and immunization35
Scottish Immunisation Recall System (SIRS)bData on recorded immunization in children when scheduled for a vaccination, including children of pre-school age36

HEPMA, Hospital Electronic Prescribing and Medicines Administration.

Data sources approved as of May 2020.

Data sources pursuing.

Figure 2

Flow diagram for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort. Primary care consultations (SMR; Scottish Morbidity Record; OOH: Out-of-hours); Hospital Admission (SICSAG: Scottish Intensive Care Society Audit Group; CO-CIN: COVID19 Clinical Information Network; RAPID: Rapid Preliminary Inpatient Data; SAS: Scottish Ambulance Service); Prescribing (PIS: Prescribing Information System; HEMPA: Hospital Electronic Prescribing and Medicines Administration); Laboratory (ECOSS: Electronic Communication of Surveillance in Scotland; RT-PCR: Reverse transcription polymerase chain reaction); Vaccine Treatment (CHSP-S: Child Health Systems Programme School; SIRS: Scottish Immunisation Recall System); Birth and Pregnancy (SBR: Scottish Birth Record; NRS: National Records of Scotland; AAS: Abortion Act Scotland).

Flow diagram for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort. Primary care consultations (SMR; Scottish Morbidity Record; OOH: Out-of-hours); Hospital Admission (SICSAG: Scottish Intensive Care Society Audit Group; CO-CIN: COVID19 Clinical Information Network; RAPID: Rapid Preliminary Inpatient Data; SAS: Scottish Ambulance Service); Prescribing (PIS: Prescribing Information System; HEMPA: Hospital Electronic Prescribing and Medicines Administration); Laboratory (ECOSS: Electronic Communication of Surveillance in Scotland; RT-PCR: Reverse transcription polymerase chain reaction); Vaccine Treatment (CHSP-S: Child Health Systems Programme School; SIRS: Scottish Immunisation Recall System); Birth and Pregnancy (SBR: Scottish Birth Record; NRS: National Records of Scotland; AAS: Abortion Act Scotland). Baseline characteristics of the population in the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort study (n = 5 431 034). Update: 23 February 2020 Missing values (%) as below. Deprivation score not available for 45 245 (0.8%) individuals. Score calculated via the Scottish Index of Multiple Deprivation (SIMD). Urban/rural score not available for 45 245 (0.8%) individuals. NHS Health Board not available for 45 245 (0.8%) individuals. Details of data sources within the different settings for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort A network established by NHS Health Boards in Scotland to provide a direct and rapid route of people with COVID-19. Data from these centres will derive from National Health Service (NHS) 24 and the COVID-19 Enhanced Surveillance dataset. Scottish Morbidity Record (SMR) including: SMR01 SMR02 COVID19 Clinical Information Network/International Severe Acute Respiratory and emerging Infection Consortium (CO-CIN/ISARIC) p HEPMA, Hospital Electronic Prescribing and Medicines Administration. Data sources approved as of May 2020. Data sources pursuing. This cohort therefore consists of specific groups of interest that are used in EAVE II sub-studies such as the COVID-19 in Pregnancy in Scotland (COPS) and for investigating ethnic and social inequalities in COVID-19.

How often have they been followed up?

The baseline GP records will be updated on a biannual to 3-monthly basis, if possible. The first update in early 2021 will contain COVID-19-specific GP codes that were created during the pandemic and were therefore missed in the initial extract. This will capture information on COVID-19 related appointments, vaccinations, therapies and vaccination-induced adverse effects. Information on influenza will also be included to facilitate analyses on the effectiveness of and safety of COVID-19-specific and pre-existing vaccines, therapies and treatments. To facilitate UK-wide research, QCOVID groups will also be added to allow validation of the QCOVID ‘living’ risk prediction model on the Scottish population. Information on shielded risk groups will also be included to assess the impact of COVID-19 on those most at risk for severe illness where a 12-month self-isolation was recommended by the UK government on 23 March 2020. Regular updates on a number of linked datasets and the underlying GP data will be undertaken on a daily, weekly or monthly basis, as available and necessary (see Table 3). Those who have transferred GPs within Scotland will stay in the cohort. Participants who die or permanently leave Scotland (and deregister from general practices) will drop out of the cohort. Characteristics of individuals lost to follow-up compared with those remaining in the cohort will also be provided in the study. Missing data will also be reported for each variable.
Table 3

Details on frequency of data linkages

Daily or weekly linkagesWeekly or monthly linkagesMonthly linkages
ECOSSSMR01SBR
NHS 24SMR02NRS births
SASPISNRS stillbirths
Serology dataNRS deathsNHS antenatal care
SICSAGCO-CINAAS
RAPIDOOH

AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR; Scottish Morbidity Record.

Details on frequency of data linkages AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR; Scottish Morbidity Record.

What has been measured?

Combining these rich data sources together provides a wealth of information on the natural history of the condition and patients’ journeys across Scotland’s NHS. We provide a high-level summary of key available data in Table 4.
Table 4

Variables captured and their relevant data sources

CategoryVariable groupSpecific variablesSource(s)
COVID-19 outcomesTestingTested; date of positive/negative test; test results; type of test; antibody tests (if available)COVID-19 Community Hubs and Assessment Centres; ECOSS; serology data; genome sequencing data; Test and Protect data
SeveritySeverity; symptoms; hospital admission; admitted to ICU; treatment in ICUNHS 24; COVID-19 Community Hubs and Assessment Centres; SMR; SAS; SICSAG; CO-CIN; RAPID; Test and Protect data; Surveys; SMR01; SMR00
MortalityDeath; cause of deathNRS deaths; SMR
TreatmentType of vaccination; date of vaccination

GP data; ECOSS;

CHSP-S; SIRS

Potential risk factorsSociodemographicAge; sex; ethnicity; country of birth; BMI; smoking; employment status; occupation; country of birth; religion; tenureGP data; 2011 Census
GeographicalData zone; socioeconomic status (SES) through Scottish Multiple Deprivation Index (SIMD)18; Urban Rural Index19; pollution exposure40; population densityGP data (use postcode to link to relevant datasets)
ClinicalComorbidities including chronic respiratory disease (with chronic obstructive pulmonary disease and asthma as subsets); chronic heart disease; chronic liver disease; chronic kidney disease; chronic neurological disease; diabetes types 1 and 2; conditions or medications causing impaired immune function; pregnancy; asplenia or dysfunction of spleen; obesity; hypertension (subsets controlled/uncontrolled hypertension); tuberculosis; multimorbidity; Charlson Comorbidity IndexGP data; SMR
MedicationsPrescription drugs including asthma (including GINA management steps and oral steroids) and COPD-related prescriptions; regular inhalers; COVID/pandemic acute therapies and chronic therapy for long-term sequelae; statins; rhinitis therapy; immunotherapy; diabetes therapy; cardiovascular disease therapy; antihypertensives; antibiotics; NSAIDs; Cox2; paracetamol; antiviral prescriptions; drugs for previous primary care consultations; polypharmacy; high-risk prescribingGP data; PIS; HEPMA
Pregnancy and babiesPregnancy indicator; miscarriage, ectopic pregnancy, pregnancy termination (incl. date, gestation, grounds); stillbirth (incl. date, gestation, cause of death); live birth (incl. date, gestation, sex of baby); congenital anomaly flag; neonatal outcomes following maternal infectionGP data; SMR; SICSAG; CO-CIN; SBR; NHS live birth; NRS births; NRS stillbirths; NHS antenatal care; AAS

AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; ICU, itensive care unit; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR, Scottish Morbidity Record; NSAID, non-steroidal anti-inflammatory drug; incl., including; HEPMA, Hospital Electronic Prescribing and Medicines Administration.

Variables captured and their relevant data sources GP data; ECOSS; CHSP-S; SIRS AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; ICU, itensive care unit; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR, Scottish Morbidity Record; NSAID, non-steroidal anti-inflammatory drug; incl., including; HEPMA, Hospital Electronic Prescribing and Medicines Administration.

What has it found?

Permissions to link these datasets were received in May 2020 and the flow of linked data began in June 2020. The initial GP data extract contained the baseline cohort and the EAVE II risk groups, which were based on the risk groups for seasonal influenza, as research at the time of extract did not know exact risk groups for COVID-19. This includes comorbidities and household characteristics, for example an indicator of living in a care home. This EAVE II risk group dataset contained more individuals than the baseline cohort, with over-representation in certain populations. This is likely to have resulted in residents being registered at multiple GP practices, people who have left Scotland or visitors. To overcome this, weights were calculated by comparing the age and sex profile in the EAVE II cohort with the age and sex profile for the 2019 NRS mid-year population estimates in Scotland. A summary of the number of EAVE II risk groups using these weights is shown in the Supplementary material, along with the individual risk groups (Supplementary Table S1, available as Supplementary data at IJE online). The following analyses were performed using these weights. Initial explorations showed that as age increased, lower levels of deprivation using SIMD quintiles slightly increased and the number of risk groups increased (Figure 3). These did not differ substantially between sexes (Figure 3).
Figure 3

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code). Since the first follow-up of COVID-19 outcomes from 1 March to 10 November, there have been a total of 835 803 (15.4%) tested, 57 416 (1.1%) with a positive test (out of the total cohort), 9847 (0.2%) hospitalized with COVID-19, 5350 (0.1%) admitted to an intensive care unit (ICU) or died with COVID-19 on the death certificate and 4726 (0.1%) who have died with COVID-19 on the death certificate within the EAVE II cohort. The proportions of these outcomes split by age and sex for the same time period show that more elderly residents have been tested with a resulting positive test (Figure 4). Elderly residents, particularly males, are also more represented in the more severe outcomes (Figure 4).
Figure 4

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code). Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code). These age profiles were repeated for deprivation levels (using SIMD quintiles), the number of risk groups and the 20 most frequent individual risk groups within the EAVE II study (Supplementary material). This showed that there were higher proportions of positive tests and more severe outcomes in more deprived areas, residents belonging to multiple risk groups and those who had comorbidities (Supplementary material, available as Supplementary data at IJE online). The map of the proportion of these outcomes by NHS Health Board demonstrated that despite high rates of testing in more rural areas in the northern and southern parts of Scotland, positive tests were low (Figure 5). The central belt had a higher proportion of positive tests out of the total baseline population and higher rates of more severe COVID-19 outcomes (Figure 5).
Figure 5

Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

All relevant R code scripts for the summary tables and figures will be made available on the EAVE II GitHub page [https://github.com/EAVE-II]. This will also contain a data dictionary for the entire EAVE cohort which will be updated when new updates and data linkages are made. We are currently working on the development of a national risk prediction algorithm to identify risk factors for poor outcomes i.e. hospitalisation and death from COVID-19, and the validation of the QCOVID-19 algorithm.

What are the main strengths and weaknesses?

The EAVE II cohort will be widely generalizable to the Scottish population as it contains all individuals registered within GP practices in Scotland, with exception of homeless, itinerant or travelling groups, those in prison, those who are institutionalized due to mental health reasons and other reasons. Regularly updating and monitoring this cohort over a long period of time will also be quick and cost effective as the underlying data sources are mainly routinely collected, quality assured and easily linkable using unique CHI numbers. This in turn means insights can be kept up to date with the rapidly evolving pandemic situation. The completeness and coverage, in terms of both population and breadth of data, are also a major strength. The key limitations are the possibility of some selection biases because of excluded patients, although this is estimated to be under 2% of the Scottish population, and the risk of residual confounding in the context of analytical epidemiological studies. Considerable care will need to be taken when making inferences about the effectiveness of interventions, because of non-randomized comparisons.

Can I get hold of the data? Where can I find out more?

Data can be accessed by contacting the corresponding author. For more information on the cohort, refer to the published EAVE II protocol. The study findings will be presented at international conferences and published in peer-reviewed journals. Profile in a nutshell The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of COVID-19, patterns of health care use and outcomes, and insights into the effectiveness and safety of vaccines and treatments for COVID-19. As far as we are aware, EAVE II is the first national end-to-end clinical surveillance platform for COVID-19 predominantly using routinely available data. This study contains all 5.4 million individuals registered with a GP in Scotland from 23 February 2020, covering 98–99% of the Scottish population. These primary care records are linked to other data sources from out-of-hours, community, emergency and secondary care, in addition to data on registrations and mortality, laboratory testing, self-report and enhanced surveillance. These data will be updated throughout the course of the pandemic. Participants who die or permanently leave Scotland (and deregister from general practices) will drop out of the cohort. Combining these rich data sources together provides a wealth of information on the natural history of the condition and patients’ journeys across Scotland’s National Health Service (NHS). Data will be hosted in Scotland’s National Safe Haven within the electronic Data Research and Innovation Service (eDRIS) of Public Health Scotland (PHS). Applicants must submit an enquiry to the corresponding author.

Supplementary Data

Supplementary data are available at IJE online.

Author Contributions

A.S. initiated the manuscript. R.H.M. and E.V. led the writing of the manuscript, and R.H.M. and C.R. led the analysis. All co-authors reviewed and contributed to the writing of the manuscript.

Funding

The original EAVE project was funded by the National Institute for Health Research Health Technology Assessment Programme (project number 13/34/14). EAVE II is funded by the Medical Research Council [MR/R008345/1] and supported by the Scottish Government. This work is supported by BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004]. BREATHE is funded through 10 the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK.

Conflict of interest

Details on competing interests are included in the study’s protocol [https://doi.org/10.1136/bmjopen-2020-039097]. Remaining co-authors (R.H.M., C.M., U.A., R.W., A.B.D., S.J.S.) do not report conflict of interest. A.D. and S.J.S. are also funded by Wellcome Trust Clinical Career Development. H.R.S. is supported by the Medical Research Council (MR/R008345/1). Click here for additional data file.
Table 1

Baseline characteristics of the population in the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort study (n = 5 431 034). Update: 23 February 2020

CharacteristicsTotal number of individuals (% of total)
Sex
 Female2733477 (50.3)
 Male2697557 (49.7)
Age group (years)
 0–4245423 (4.5)
 5–14574389 (10.6)
 15–24624070 (11.5)
 25–441479594 (27.2)
 45–641503617 (27.7)
 65–74563605 (10.4)
 75–84323812 (6.0)
>85116524 (2.1)
Deprivation quintilea
 1: most deprived1100521 (20.3)
 21074842 (19.8)
 31050369 (19.3)
 41079282 (19.9)
 5: least deprived1080775 (19.9)
Urban/rural scoreb
 1: large urban areas1920932 (35.4)
 2: other urban areas1959281 (36.1)
 3: accessible small towns501557 (9.2)
 4: remote small towns257264 (4.7)
 5: accessible rural486665 (9.0)
 6: remote rural260090 (4.8)

Missing values (%) as below.

Deprivation score not available for 45 245 (0.8%) individuals. Score calculated via the Scottish Index of Multiple Deprivation (SIMD).

Urban/rural score not available for 45 245 (0.8%) individuals.

NHS Health Board not available for 45 245 (0.8%) individuals.

  11 in total

1.  COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.

Authors:  Steven Kerr; Eleftheria Vasileiou; Chris Robertson; Aziz Sheikh
Journal:  J Glob Health       Date:  2022-07-09       Impact factor: 7.664

2.  Deriving and validating a risk prediction model for long COVID-19: protocol for an observational cohort study using linked Scottish data.

Authors:  Luke Daines; Rachel H Mulholland; Eleftheria Vasileiou; Vicky Hammersley; David Weatherill; Srinivasa Vittal Katikireddi; Steven Kerr; Emily Moore; Elisa Pesenti; Jennifer K Quint; Syed Ahmar Shah; Ting Shi; Colin R Simpson; Chris Robertson; Aziz Sheikh
Journal:  BMJ Open       Date:  2022-07-06       Impact factor: 3.006

3.  Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection.

Authors:  Frank M Sullivan; Agnes Tello; Petra Rauchhaus; Virginia Hernandez Santiago; Fergus Daly
Journal:  J Circ Biomark       Date:  2022-05-03

4.  Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study.

Authors:  Ting Shi; Jiafeng Pan; Eleftheria Vasileiou; Chris Robertson; Aziz Sheikh
Journal:  Lancet Respir Med       Date:  2022-01-13       Impact factor: 30.700

5.  External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland.

Authors:  Colin R Simpson; Chris Robertson; Steven Kerr; Ting Shi; Eleftheria Vasileiou; Emily Moore; Colin McCowan; Utkarsh Agrawal; Annemarie Docherty; Rachel Mulholland; Josie Murray; Lewis Duthie Ritchie; Jim McMenamin; Julia Hippisley-Cox; Aziz Sheikh
Journal:  Thorax       Date:  2021-11-15       Impact factor: 9.102

6.  Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.

Authors:  Aziz Sheikh; Steven Kerr; Mark Woolhouse; Jim McMenamin; Chris Robertson
Journal:  Lancet Infect Dis       Date:  2022-04-22       Impact factor: 71.421

7.  Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.

Authors:  Pilar T V Florentino; Tristan Millington; Thiago Cerqueira-Silva; Chris Robertson; Vinicius de Araújo Oliveira; Juracy B S Júnior; Flávia J O Alves; Gerson O Penna; Srinivasa Vital Katikireddi; Viviane S Boaventura; Guilherme L Werneck; Neil Pearce; Colin McCowan; Christopher Sullivan; Utkarsh Agrawal; Zoe Grange; Lewis D Ritchie; Colin R Simpson; Aziz Sheikh; Mauricio L Barreto; Igor Rudan; Manoel Barral-Netto; Enny S Paixão
Journal:  Lancet Infect Dis       Date:  2022-08-08       Impact factor: 71.421

8.  Risk of COVID-19 hospitalizations among school-aged children in Scotland: A national incident cohort study.

Authors:  Ting Shi; Jiafeng Pan; Emily Moore; Srinivasa Vittal Katikireddi; Annemarie B Docherty; Lynda Fenton; Colin McCowan; Utkarsh Agrawal; Steven Kerr; Syed Ahmar Shah; Sarah J Stock; Colin R Simpson; Chris Robertson; Aziz Sheikh
Journal:  J Glob Health       Date:  2022-09-23       Impact factor: 7.664

9.  Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.

Authors:  Utkarsh Agrawal; Stuart Bedston; Colin McCowan; Jason Oke; Lynsey Patterson; Chris Robertson; Ashley Akbari; Amaya Azcoaga-Lorenzo; Declan T Bradley; Adeniyi Francis Fagbamigbe; Zoe Grange; Elliott C R Hall; Mark Joy; Srinivasa Vittal Katikireddi; Steven Kerr; Lewis Ritchie; Siobhán Murphy; Rhiannon K Owen; Igor Rudan; Syed Ahmar Shah; Colin R Simpson; Fatemeh Torabi; Ruby S M Tsang; Simon de Lusignan; Ronan A Lyons; Dermot O'Reilly; Aziz Sheikh
Journal:  Lancet       Date:  2022-10-15       Impact factor: 202.731

10.  Cohort Profile: The COVID-19 in Pregnancy in Scotland (COPS) dynamic cohort of pregnant women to assess effects of viral and vaccine exposures on pregnancy.

Authors:  Sarah J Stock; Jade Carruthers; Cheryl Denny; Jack Donaghy; Anna Goulding; Lisa E M Hopcroft; Leanne Hopkins; Rachel Mulholland; Utkarsh Agrawal; Bonnie Auyeung; Srinivasa Vittal Katikireddi; Colin McCowan; Josie Murray; Chris Robertson; Aziz Sheikh; Ting Shi; Colin R Simpson; Eleftheria Vasileiou; Rachael Wood
Journal:  Int J Epidemiol       Date:  2022-10-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.